What is dermatomyositis?

What is Dermatomyositis?

Dermatomyositis is an inflammatory myopathy characterized by distinctive skin manifestations and progressive proximal muscle weakness, with potential for life-threatening complications including interstitial lung disease, cardiac involvement, and associated malignancy in approximately 20% of adult cases. 1, 2

Core Clinical Features

Pathognomonic Cutaneous Manifestations

The diagnosis hinges on recognizing characteristic skin findings that often precede muscle symptoms:

• Heliotrope rash: Violaceous periorbital edema, particularly prominent in anti-Mi-2 positive patients 3, 2
• Gottron's papules: Erythematous to violaceous papules over the extensor surfaces of metacarpophalangeal and interphalangeal joints 1, 2
• Gottron's sign: Erythematous macules in the same distribution without papular elevation 1
• V-sign: Erythema over the anterior chest, frequently observed in anti-Mi-2 positive disease 3, 2
• Shawl sign: Erythema over the shoulders and upper back 1
• Mechanic's hands: Hyperkeratotic, cracked skin on palms and fingers, associated with antisynthetase syndrome 3, 2
• Periungual changes: Nailfold telangiectasias and splinter hemorrhages; nailfold capillaroscopy predicts disease severity 3, 2

Photosensitivity is common, with ultraviolet light exposure potentially triggering disease onset, particularly in anti-Mi-2 positive patients. 3, 2

Muscular Involvement

• Symmetric proximal muscle weakness causing difficulty rising from a chair, climbing stairs, lifting objects overhead, or combing hair 1, 3, 2
• Progressive onset developing over weeks to months 1, 3
• Preservation of distal muscle strength, which distinguishes dermatomyositis from inclusion-body myositis 2
• Neck flexors are characteristically weaker than neck extensors 1

Diagnostic Criteria

The formal diagnosis requires meeting specific criteria established by Bohan & Peter, needing ≥4 of 5 features for definite diagnosis: 2

1. Characteristic skin findings
2. Proximal muscle weakness
3. Elevated muscle enzyme levels (CK, aldolase, LDH, AST, ALT)
4. Myopathic pattern on electromyography (short-duration, low-amplitude, polyphasic motor unit potentials with increased spontaneous activity)
5. Endomysial mononuclear inflammatory infiltrate on muscle biopsy

The 2017 EULAR/ACR classification criteria provide a probability-based scoring system, with a score ≥5.5 (without biopsy) or ≥6.7 (with biopsy) corresponding to ≥55% probability of idiopathic inflammatory myopathy ("probable IIM"), and scores ≥7.5 or ≥8.7 corresponding to ≥90% probability ("definite IIM"). 1

Myositis-Specific Antibodies and Clinical Phenotypes

Antibody testing is critical for risk stratification and predicting extramuscular manifestations:

• Anti-Jo-1 (and other antisynthetase antibodies): Present in ~20% of adult patients; defines antisynthetase syndrome with interstitial lung disease, arthritis, Raynaud phenomenon, mechanic's hands, and fever 3, 2
• Anti-Mi-2: Found in <10% of adults; indicates classic dermatomyositis with prominent skin involvement, good response to therapy, low malignancy risk, and minimal interstitial lung disease 3, 2
• Anti-TIF1-γ (anti-p155/140): Strongly associated with malignancy in adults (but not children); necessitates comprehensive cancer screening 3, 2
• Anti-MDA5: Associated with rapidly progressive interstitial lung disease requiring urgent pulmonary monitoring 3, 2
• Anti-SRP: Indicates necrotizing myopathy with acute onset and dilated cardiomyopathy 3
• Anti-NXP2: Associated with calcinosis and malignancy risk 4, 5

Approximately 80% of patients will have at least one detectable myositis-specific antibody, which determines prognosis, extramuscular manifestations to monitor, and treatment aggressiveness required. 3

Life-Threatening Extramuscular Manifestations

Pulmonary Complications

• Interstitial lung disease is common, especially with antisynthetase antibodies (anti-Jo-1, anti-PL-7, anti-PL-12) and anti-MDA5 antibodies 3, 2
• Rapidly progressive ILD with anti-MDA5 requires immediate high-resolution CT, pulmonary function testing, and aggressive immunosuppression 3, 4
• Aspiration pneumonia secondary to dysphagia and cricopharyngeal dysfunction 2

Cardiac Involvement

• Arrhythmias including asymptomatic sinus tachycardia detectable on electrocardiography 3, 2
• Conduction abnormalities may be present without overt symptoms 3, 2
• Diastolic dysfunction visible on echocardiography 3, 2
• Myocarditis identified in autopsy studies 3, 2
• Patients with anti-SRP antibodies require complete cardiac evaluation including troponin, ECG, and echocardiogram 3

Gastrointestinal Complications

• Dysphagia from cricopharyngeal muscle dysfunction and esophageal dysmotility 1, 2
• Vasculopathy in juvenile dermatomyositis can lead to bowel ischemia and infarction 2

Malignancy Association

Adult-onset dermatomyositis carries an approximately 20% risk of associated malignancy, with highest risk in anti-TIF1-γ positive patients and lowest risk in anti-Mi-2 positive patients and juvenile dermatomyositis. 1, 2 Malignancy is often diagnosed within 1 year of dermatomyositis diagnosis. 1 Comprehensive cancer screening at diagnosis and during follow-up is mandatory. 2, 4

Clinical Variants

Amyopathic Dermatomyositis

• Classic dermatomyositis rash without muscle weakness 2
• Normal muscle enzyme levels and EMG within the first two years of disease 2
• Interstitial lung disease may still develop despite absence of myositis 2
• Malignancy risk is lower than classic dermatomyositis but remains present 2
• Patients require comprehensive malignancy screening and ILD monitoring despite lack of muscle involvement 2

Hypomyopathic Dermatomyositis

• No clinical muscle weakness, but subclinical inflammation evidenced by mild CK elevation, EMG abnormalities, or MRI changes 2

Juvenile Dermatomyositis

• Occurs in individuals <18 years with skin and muscle features similar to adult disease 2
• Higher incidence of calcinosis cutis, vasculopathy, and dysphonia 3, 2
• Nailfold capillaroscopy is especially useful for predicting severity and monitoring disease course 2
• Lower malignancy risk compared to adult-onset disease 2

Pathophysiology

The disease is characterized by activation of innate and adaptive immune mechanisms with strong activation of the type I interferon pathway. 6 The precise etiologic link between malignancy and dermatomyositis is likely autoimmune, with responsiveness to immunosuppressive therapy supporting this etiology. 1 Recent evidence shows that sera from patients with dermatomyositis can directly induce muscle weakness, impair mitochondrial respiration, and trigger local cytokine production (TNF-α, IL-1β) in isolated muscle tissue. 7

Assessment Tools for Disease Activity

Muscle Strength Evaluation

• Manual Muscle Test (MMT): Scores 26 muscle groups bilaterally using UK Medical Research Council System scale (0-5) 1
• MMT-8: Shortened version scoring 8 proximal, distal, and axial muscle groups on one side 1
• Test bilaterally: neck flexion/extension, shoulder abduction, elbow flexion/extension, wrist flexion/extension, hip flexion/extension, hip abduction/adduction, knee flexion/extension, ankle dorsiflexion, and plantar flexion 1

Skin Disease Assessment

• Cutaneous Assessment Tool: Comprehensive tool assessing "activity lesions" (Gottron papules, shawl sign, ulcerations) and "damage lesions" (atrophy, hypopigmentation/hyperpigmentation, lipoatrophy) using weighted scale 1
• Dermatomyositis Skin Severity Index and Cutaneous Dermatomyositis Disease Area and Severity Index for adults 1

Functional Assessment

• Stanford Health Assessment Questionnaire (HAQ): Self-survey of activities of daily living with score range 0-3.0 (0.1-1.0 = mild disability; 1.01-2.0 = moderate disability; 2.01-3.0 = severe disability) 1

Global Disease Activity

• Visual analog scale (0-10) or 5-point Likert scale (0-4) for overall disease activity based on history, physical examination, laboratory results, and medical therapy 1

Common Pitfalls

• Do not dismiss skin findings in the absence of muscle weakness—amyopathic dermatomyositis still requires malignancy screening and ILD monitoring 2
• Do not delay antibody testing—myositis-specific antibodies guide risk stratification and monitoring strategies 3, 4
• Do not overlook cardiac screening—asymptomatic arrhythmias and conduction abnormalities are common 3, 2
• Do not assume low malignancy risk without antibody data—anti-TIF1-γ positive patients require exhaustive cancer screening 3, 2
• Do not wait for muscle biopsy to initiate treatment when clinical and serological features are diagnostic—early treatment improves outcomes 4, 6